We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
+38.45%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$617M
AUM Growth
+$270M
(+78%)
Cap. Flow
+$81.4M
Cap. Flow % of AUM
Cap. Flow %
13.2%
Top 10 Holdings %
Top 10 Hldgs %
38.27%
Holding
109
New
46
Increased
22
Reduced
16
Closed
21
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$15.9M |
| 2 |
Abbott
ABT
|
+$12.9M |
| 3 |
DBV Technologies S.A. American Depositary Shares
DBVT
|
+$8.68M |
| 4 |
CELG
Celgene Corp
CELG
|
+$8.12M |
| 5 |
CYNO
Cynosure, Inc. Class A
CYNO
|
+$7.79M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$12.1M |
| 2 |
Medtronic
MDT
|
+$8.68M |
| 3 |
bluebird bio
BLUE
|
+$6.15M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$5.68M |
| 5 |
CONMED
CNMD
|
+$5.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.34% |
| 2 | Miscellaneous | 44.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.9B
| $49.7M | 8.06% |
750,000
+350,000
| +88% | +$21.7M |
2016 Q1
2 quarters
|
|
2
PUT
iShares Biotechnology ETF
IBB
$11.2B
| $28.9M | 4.69% |
+300,000
| New | +$28.5M |
2016 Q3
0 quarters
|
|
3
PUT
iShares Russell 2000 ETF
IWM
$75.2B
| $27.9M | 4.53% |
225,000
-125,000
| -36% | -$15.2M |
2016 Q1
2 quarters
|
|
4
PUT
Sarepta Therapeutics
SRPT
$2.01B
| $24.6M | 3.98% |
400,000
+100,000
| +33% | +$3.02M |
2016 Q2
1 quarter
|
|
|
5
CALL
Sarepta Therapeutics
SRPT
$2.01B
| $21.5M | 3.49% |
350,000
+250,000
| +250% | +$7.56M |
2016 Q2
1 quarter
|
|
6
CALL
Biogen
BIIB
$36.6B
| $20.3M | 3.3% |
+65,000
| New | +$19.3M |
2016 Q3
0 quarters
|
|
|
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
| $18M | 2.92% |
500,000
+50,000
| +11% | +$1.07M |
2016 Q1
2 quarters
|
|
|
8
Zimmer Biomet
ZBH
$18.3B
| $16.3M | 2.64% |
+128,750
| New | +$15.9M |
2016 Q3
0 quarters
|
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
| $14.7M | 2.38% |
120,000
+30,000
| +33% | +$3.86M |
2016 Q1
2 quarters
|
|
|
NUVA
10
DELISTED
NuVasive, Inc.
NUVA
| $14M | 2.27% |
210,000
+60,000
| +40% | +$3.82M |
2014 Q3
8 quarters
|
|
|
GWPH
11
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $13.3M | 2.15% |
+100,000
| New | +$9.6M |
2016 Q3
0 quarters
|
|
|
12
Abbott
ABT
$178B
| $12.7M | 2.06% |
+300,000
| New | +$12.9M |
2016 Q3
0 quarters
|
|
|
AERI
13
CALL
DELISTED
Aerie Pharmaceuticals
AERI
| $11.3M | 1.84% |
+300,000
| New | +$6.62M |
2016 Q3
0 quarters
|
|
|
SPNC
14
DELISTED
Spectranetics Corp
SPNC
| $10.9M | 1.77% |
435,000
+60,000
| +16% | +$1.4M |
2015 Q3
4 quarters
|
|
15
CALL
Bristol-Myers Squibb
BMY
$124B
| $10.8M | 1.75% |
+200,000
| New | +$12.8M |
2016 Q3
0 quarters
|
|
16
CALL
Boston Scientific
BSX
$61.5B
| $10.7M | 1.74% |
450,000
+100,000
| +29% | +$2.39M |
2016 Q2
1 quarter
|
|
|
CELG
17
DELISTED
Celgene Corp
CELG
| $10.5M | 1.7% |
100,000
+75,000
| +300% | +$8.12M |
2016 Q1
2 quarters
|
|
|
WMGI
18
DELISTED
Wright Medical Group Inc
WMGI
| $10.4M | 1.69% |
425,000
+175,000
| +70% | +$4.03M |
2015 Q4
3 quarters
|
|
19
Edwards Lifesciences
EW
$52.7B
| $10.2M | 1.66% |
255,000
| – | – |
2016 Q2
1 quarter
|
|
20
Puma Biotechnology
PBYI
$549M
| $10.1M | 1.63% |
+150,000
| New | +$7.58M |
2016 Q3
0 quarters
|
|
|
21
Boston Scientific
BSX
$61.5B
| $9.5M | 1.54% |
400,000
+75,000
| +23% | +$1.79M |
2016 Q1
2 quarters
|
|
22
CALL
Merck
MRK
$347B
| $9.36M | 1.52% |
+157,200
| New | +$9.19M |
2016 Q3
0 quarters
|
|
|
ISEE
23
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.23M | 1.5% |
+200,000
| New | +$11.3M |
2016 Q3
0 quarters
|
|
|
24
Sarepta Therapeutics
SRPT
$2.01B
| $9.21M | 1.49% |
150,000
-50,000
| -25% | -$1.51M |
2016 Q2
1 quarter
|
|
|
25
DBV Technologies S.A. American Depositary Shares
DBVT
$665M
| $9.08M | 1.47% |
+25,000
| New | +$8.68M |
2016 Q3
0 quarters
|
|
Similar funds
AFS
E
Ghost Tree Capital's Q3 2016 Portfolio in Review
As of Q3 2016, Ghost Tree Capital held 109 positions worth $617M, up 78% from $346M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Ghost Tree Capital deployed $81.4M of net new capital in Q3 2016, opening 46 new positions and adding to 22 existing holdings. Its largest new stake was Zimmer Biomet: 128,750 shares worth $16.3M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 60% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was bluebird bio, an estimated $6.15M trimmed.
- Ghost Tree Capital's largest Q3 2016 buy was Zimmer Biomet: 128,750 shares worth $16.3M.
- Ghost Tree Capital added most to Celgene Corp in Q3 2016, an estimated $8.12M increase.
- Ghost Tree Capital's biggest Q3 2016 reduction was bluebird bio, cutting an estimated $6.15M.
- Ghost Tree Capital fully exited IVERIC bio, Inc. Common Stock in Q3 2016, selling an estimated $12.1M.
- Ghost Tree Capital's ten largest holdings make up 38% of its $617M portfolio in Q3 2016.
- Ghost Tree Capital opened 46 new positions and closed 21 in Q3 2016.
- Ghost Tree Capital's portfolio value rose 78% quarter-over-quarter to $617M.
Based on Ghost Tree Capital's 13F filing for Q3 2016, filed 14 Nov 2016.